These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31953463)

  • 21. A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer.
    Lu H; Zha S; Zhang W; Wang Q; Jiang D; Xu X; Zheng X; Qiu M; Shan C
    BMC Cancer; 2021 Jul; 21(1):830. PubMed ID: 34275458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial.
    Zhao Y; Lv F; Chen S; Wang Z; Zhang J; Zhang S; Cao J; Wang L; Cao E; Wang B; Hu X
    BMC Cancer; 2018 Oct; 18(1):1019. PubMed ID: 30348118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.
    Lluch A; Alvarez I; Muñoz M; Seguí MÁ; Tusquets I; García-Estévez L
    Crit Rev Oncol Hematol; 2014 Jan; 89(1):62-72. PubMed ID: 24071503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
    Tamura K; Inoue K; Masuda N; Takao S; Kashiwaba M; Tokuda Y; Iwata H; Yamamoto N; Aogi K; Saeki T; Nakayama T; Sato N; Toyama T; Ishida T; Arioka H; Saito M; Ohno S; Yamauchi H; Yamada K; Watanabe J; Ishiguro H; Fujiwara Y
    Cancer Sci; 2017 May; 108(5):987-994. PubMed ID: 28256066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanoparticle albumin-bound paclitaxel versus solvent-based paclitaxel in breast cancer: A protocol for systemic review and meta-analysis.
    Li B; Chen X; Ding T; Liu Y; Ma T; Zhang G; Wang X
    Medicine (Baltimore); 2021 Feb; 100(7):e24514. PubMed ID: 33607781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective.
    Sachdev JC; Jahanzeb M
    Clin Breast Cancer; 2016 Apr; 16(2):73-81. PubMed ID: 26603443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.
    Dranitsaris G; Cottrell W; Spirovski B; Hopkins S
    J Oncol Pharm Pract; 2009 Jun; 15(2):67-78. PubMed ID: 19036903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
    Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
    Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers-Improvements in Clinical Efficacy and Safety.
    Hassan MS; Awasthi N; Ponna S; von Holzen U
    Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer.
    Takashima T; Kawajiri H; Nishimori T; Tei S; Nishimura S; Yamagata S; Tokunaga S; Mizuyama Y; Sunami T; Tezuka K; Ikeda K; Ogawa Y; Kashiwagi S; Noda S; Onoda N; Ishikawa T; Kudoh S; Takada M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Jan; 38(1):379-383. PubMed ID: 29277798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer.
    Yamamoto S; Maeda N; Nagashima Y; Kubo H; Sato Y; Matsui H; Inoue Y; Shindo Y; Kanekiyo S; Sakamoto K; Suzuki N; Takeda S; Ueno T; Yoshino S; Hazama S; Oka M; Nagano H
    Breast Cancer; 2017 Nov; 24(6):783-789. PubMed ID: 28439763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study.
    Jain MM; Gupte SU; Patil SG; Pathak AB; Deshmukh CD; Bhatt N; Haritha C; Govind Babu K; Bondarde SA; Digumarti R; Bajpai J; Kumar R; Bakshi AV; Bhattacharya GS; Patil P; Subramanian S; Vaid AK; Desai CJ; Khopade A; Chimote G; Bapsy PP; Bhowmik S
    Breast Cancer Res Treat; 2016 Feb; 156(1):125-34. PubMed ID: 26941199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.
    Megerdichian C; Olimpiadi Y; Hurvitz SA
    Cancer Treat Rev; 2014 Jun; 40(5):614-25. PubMed ID: 24560997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcomes of neoadjuvant chemotherapy for patients with breast cancer: Tri-weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide: a retrospective observational study.
    Shizuku M; Shibata M; Shimizu Y; Takeuchi D; Mizuno Y
    Nagoya J Med Sci; 2020 Aug; 82(3):457-467. PubMed ID: 33132430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival.
    Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P; McGuire JR; Iglesias J
    Clin Breast Cancer; 2012 Oct; 12(5):313-21. PubMed ID: 22728026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is nab-paclitaxel better than conventional taxanes as neoadjuvant therapy for breast cancer? A meta-analysis.
    Li Y; Lu X; Lin Q; Li W
    J Int Med Res; 2020 Aug; 48(8):300060520943473. PubMed ID: 32762463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer.
    Seidman AD; Conlin AK; Bach A; Moynahan ME; Lake D; Forero A; Wright GS; Hackney MH; Clawson A; Norton L; Hudis CA
    Clin Breast Cancer; 2013 Aug; 13(4):239-246.e1. PubMed ID: 23829890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).
    Roy V; LaPlant BR; Gross GG; Bane CL; Palmieri FM;
    Ann Oncol; 2009 Mar; 20(3):449-53. PubMed ID: 19087987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial.
    Sonoda T; Umeda Y; Demura Y; Tada T; Nakashima K; Anzai M; Yamaguchi M; Shimada A; Ohi M; Honjo C; Waseda Y; Akai M; Ishizuka T
    Cancer Med; 2023 Jun; 12(12):13041-13053. PubMed ID: 37081729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance).
    Rugo HS; Barry WT; Moreno-Aspitia A; Lyss AP; Cirrincione C; Leung E; Mayer EL; Naughton M; Toppmeyer D; Carey LA; Perez EA; Hudis C; Winer EP
    J Clin Oncol; 2015 Jul; 33(21):2361-9. PubMed ID: 26056183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.